Clinical Trials
7
Active:0
Completed:7
Trial Phases
2 Phases
Phase 1:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 3
1 (14.3%)A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold
Phase 3
Completed
- Conditions
- Nasal Congestion Associated With the Common Cold
- Interventions
- Drug: Placebo tablets
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Perrigo Company
- Target Recruit Count
- 565
- Registration Number
- NCT01744106
- Locations
- 🇺🇸
Emmaus Research Center, Anaheim, California, United States
🇺🇸WCCT Global, LLC, Costa Mesa, California, United States
🇺🇸Advanced Clinical Research - Boise, Boise, Idaho, United States
Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Perrigo Company
- Target Recruit Count
- 34
- Registration Number
- NCT00804401
Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Perrigo Company
- Target Recruit Count
- 30
- Registration Number
- NCT00803946
Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Perrigo Company
- Target Recruit Count
- 30
- Registration Number
- NCT00804440
Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Perrigo Company
- Target Recruit Count
- 34
- Registration Number
- NCT00803764
- Prev
- 1
- 2
- Next
News
Study Reveals Morning-After Pill Ingredient Ulipristal Acetate Can Induce Abortions
A groundbreaking study published in The New England Journal of Medicine demonstrates that ulipristal acetate, the active ingredient in ella emergency contraception, can effectively induce abortions with a 97% success rate.